US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

220.32

-7.4300-3.26%

Volume:607.24K

Turnover:130.27M

Market Cap:556.19M

PE:- -

High:223.71

Open:220.01

Low:208.30

Close:227.75

52wk High:341.93

52wk Low:102.35

Shares:2.52M

Float Shares:2.52M

Volume Ratio:1.89

T/O Rate:24.05%

Dividend:0.91

Dividend Rate:0.41%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

VTv Therapeutics Gets FDA Orphan Drug Designation for Sickle Cell Candidate

MT Newswires Live

Valneva Shrugs Off U.K. Revocation of Chikungunya Vaccine License

Fisher & Paykel Healthcare sets date for half‑year 2026 results

vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease

Vital Healthcare Property Trust Sharpens Governance After Internalisation

SCYNEXIS: Advancing Pipeline and Strong Funding Underpin Buy Rating; $32 Price Target Reaffirmed

Sector Update: Healthcare

MT Newswires Live

Exchange-Traded Funds Lower as US Equities Decline After Midday

MT Newswires Live

VERAXA Biotech (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing

New Abdominoplasty Trial Signals Steady Demand in Procedure-Driven Healthcare

Community Healthcare management to meet virtually with Truist

Novartis announces FDA approval of Rhapsido for symptomatic dermographism

Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)

Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST) and Stryker (SYK)

Ultragenyx Monetizes FDA Priority Review Voucher Asset

Clearmind Medicine submits psychedelic therapy recommendations to FDA

Sector Update: Healthcare Stocks Flat to Higher Pre-Bell Wednesday

MT Newswires Live

Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA

AbbVie’s telisotuzumab adizutecan gets two FDA Breakthrough Therapy Designations

Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (BBIO) and Vaxcyte (PCVX)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/LABU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":220.32,"timestamp":1791480474923,"preClose":227.75,"halted":0,"volume":607236,"delay":0,"changeRate":-0.032623490669593885,"floatShares":2524486,"shares":2524486,"eps":0,"marketStatus":"Trading","change":-7.43,"latestTime":"10-08 13:27:58 EDT","open":220.01,"high":223.7074,"low":208.3,"amount":130273023.06312001,"amplitude":0.06765,"askPrice":220.8,"askSize":440,"bidPrice":220.12,"bidSize":130,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791489600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":227.75,"sharesOutstanding":3074486,"nav":230.529,"aum":581967299.18,"dividendRate":0.004135,"bidAskSpread":0.002401,"preHourTrading":{"tag":"盘前","latestPrice":220.18,"preClose":227.75,"latestTime":"09:29 EDT","volume":6169,"amount":1385605.45651,"timestamp":1791466199999,"change":-7.57,"changeRate":-0.033238,"amplitude":0.038727},"postHourTrading":{"tag":"盘后","latestPrice":228.7,"preClose":227.75,"latestTime":"19:59 EDT","volume":2729,"amount":623483.6155,"timestamp":1791417573520,"change":0.95,"changeRate":0.004171,"amplitude":0.004911},"volumeRatio":1.886561,"impliedVol":0.9924,"impliedVolPercentile":0.7928},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":2524486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.886561,"shares":2524486,"dividePrice":0.911,"high":223.7074,"amplitude":0.06765,"preClose":227.75,"low":208.3,"week52Low":102.3547,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":220.32,"committee":-0.54386,"eps":0,"divideRate":0.004135,"volume":607236,"delay":0,"ttmEps":0,"open":220.01,"prevYearClose":159.39,"prevWeekClose":248.72,"prevMonthClose":265.79,"prevQuarterClose":265.79,"fiveDayClose":249.65,"twentyDayClose":266,"sixtyDayClose":277.55},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673048124","title":"VTv Therapeutics Gets FDA Orphan Drug Designation for Sickle Cell Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2673048124","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673048124?lang=en_us&edition=fundamental","pubTime":"2026-10-08 04:53","pubTimestamp":1791406430,"startTime":"0","endTime":"0","summary":"VTv Therapeutics (VTVT) said the US Food and Drug Administration granted orphan drug designation to HPPD, its investigational oral treatment for sickle cell disease.Preclinical studies conducted at Au","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4539","BK4588","LENZ","BK4585","VTVT","LABU","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673048653","title":"Valneva Shrugs Off U.K. Revocation of Chikungunya Vaccine License","url":"https://stock-news.laohu8.com/highlight/detail?id=2673048653","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673048653?lang=en_us&edition=fundamental","pubTime":"2026-10-08 04:33","pubTimestamp":1791405206,"startTime":"0","endTime":"0","summary":"An update from Valneva ( ($FR:VLA) ) is now available. Valneva said the U.K. Medicines and Healthcare products Regulatory Agency has revoked the ma...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/valneva-shrugs-off-u-k-revocation-of-chikungunya-vaccine-license?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/valneva-shrugs-off-u-k-revocation-of-chikungunya-vaccine-license?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4588","XLV","BK4585","BK4581","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673048621","title":"Fisher & Paykel Healthcare sets date for half‑year 2026 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2673048621","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673048621?lang=en_us&edition=fundamental","pubTime":"2026-10-08 04:17","pubTimestamp":1791404255,"startTime":"0","endTime":"0","summary":"The latest update is out from Fisher & Paykel Healthcare Corporation Limited ( ($NZ:FPH) ). Fisher & Paykel Healthcare has scheduled the release of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fisher-paykel-healthcare-sets-date-for-halfyear-2026-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fisher-paykel-healthcare-sets-date-for-halfyear-2026-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","XLV","XBI","BK8004","LABU","FPH.NZ","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673010917","title":"vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2673010917","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673010917?lang=en_us&edition=fundamental","pubTime":"2026-10-08 04:01","pubTimestamp":1791403260,"startTime":"0","endTime":"0","summary":"Milestone supports partnering discussions for HPPD as the Company continues to prioritize its lead late-stage type 1 diabetes (T1D) program, cadisegliatinHIGH POINT, N.C., Oct.  07, 2026 (GLOBE NEWSWI","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/07/3376824/0/en/vtv-therapeutics-announces-fda-orphan-drug-designation-for-hppd-in-sickle-cell-disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4585","VTVT","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673618010","title":"Vital Healthcare Property Trust Sharpens Governance After Internalisation","url":"https://stock-news.laohu8.com/highlight/detail?id=2673618010","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673618010?lang=en_us&edition=fundamental","pubTime":"2026-10-08 03:47","pubTimestamp":1791402455,"startTime":"0","endTime":"0","summary":"Vital Healthcare Property ( ($NZ:VHP) ) has shared an update. Vital Healthcare Property Trust is undertaking an investor governance roadshow to upd...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vital-healthcare-property-trust-sharpens-governance-after-internalisation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vital-healthcare-property-trust-sharpens-governance-after-internalisation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VHP.NZ","XLV","BK8073","XBI","BK8059","BK4588","BK4581","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673012046","title":"SCYNEXIS: Advancing Pipeline and Strong Funding Underpin Buy Rating; $32 Price Target Reaffirmed","url":"https://stock-news.laohu8.com/highlight/detail?id=2673012046","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673012046?lang=en_us&edition=fundamental","pubTime":"2026-10-08 02:05","pubTimestamp":1791396325,"startTime":"0","endTime":"0","summary":"SCYNEXIS, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim Group maintained a Buy...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/scynexis-advancing-pipeline-and-strong-funding-underpin-buy-rating-32-price-target-reaffirmed-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/scynexis-advancing-pipeline-and-strong-funding-underpin-buy-rating-32-price-target-reaffirmed-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LABU","BK4581","XLV","BK4585","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673014593","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2673014593","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673014593?lang=en_us&edition=fundamental","pubTime":"2026-10-08 01:10","pubTimestamp":1791393056,"startTime":"0","endTime":"0","summary":"Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 1.6% and the State Street Health Care Select Sector SPDR ETF  advancing 1.7%.The iShares Biotechnology ETF  increased 0.8%.In corporate news, Halozyme Therapeutics  shares rose 1.8% after the company said it has been awarded an injunction by the specialized Dutch patent court in The Hague that stops manufacture and sale of Merck's  Keytruda SC in multiple European markets. Merck shares were up 1%.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4533","LU0648001328.SGD","BK4588","LU0098860793.USD","LU2461242641.AUD","SG9999015358.SGD","LU0106261372.USD","LU2125909247.SGD","LU2125909593.SGD","LU2125154778.USD","LU1035773651.USD","LU1066051498.USD","LU2491049909.HKD","LU0289961442.SGD","LU0122379950.USD","LU0868494617.USD","BK4581","LU0265550946.USD","IE0002141913.USD","SG9999013999.USD","LU1989772840.SGD","RXL","LU1023059063.AUD","LU2361044865.SGD","LU0511384066.AUD","LU1941712264.USD","LU0289739343.SGD","LU0965509283.SGD","IE00BLSP4239.USD","LU2125154935.USD","LU0861579265.USD","BK4550","LU0058720904.USD","LU0472753341.HKD","IE00BBT3K403.USD","LU2468319806.SGD","XLV","LU1917777945.USD","IE0009355771.USD","LU0208291251.USD","LU1093756325.SGD","LU2491050154.USD","IE00BLSP4452.SGD","LU0234572021.USD","FFOX","GDOC","HRTS","LU2324357040.USD","LU1061106388.HKD","LU0238689110.USD","LU0965509101.SGD","IHE","LU0965508806.USD","IE00BJJMRZ35.SGD","LU1291159041.SGD","IE00BN8TJ469.HKD","BK4007","FHLC","PPH","IE00B4R5TH58.HKD","LU0203347892.USD","LU1934455277.USD","TRUH","HALO","LU0069063385.USD","PAWZ","LU1989772923.USD","LU1066051225.USD","LU1983299246.USD","LU0320765646.SGD","IE00B1BXHZ80.USD","LU2112291526.USD","BK4534","LU2106854487.HKD","SG9999001176.USD","SG9999001440.SGD","BK4559","LU1069347547.HKD","LU0072461881.USD","LU0070302665.USD","IE00BJT1NW94.SGD","LU1974910355.USD","LU2023250504.SGD","LU0211331839.USD","LU1585245621.USD","BK4585","SG9999002224.SGD","LU1093756168.USD","LU1941712348.USD","BMED","SG9999014542.SGD","SG9999001176.SGD","LU0006306889.USD","LU0057025933.USD","LU1037948897.HKD","XBI","LU2357627491.SGD","LU2417539215.USD","BK4516","LU2456880835.USD","SGXZ57979304.SGD","LU1032466523.USD","SG9999002232.USD","LU0265550359.USD","LU0266013472.USD","SG9999014575.USD","SG9999014567.USD","LU2491050071.SGD","LU0320765489.SGD","LU0130102774.USD","LU0868494708.USD","LU1430594728.SGD","LU1037948541.HKD","LU2089984988.USD","LU2360032135.SGD","BK4139","IE000M9KFDE8.USD","LU0162691827.USD","LU0203345920.USD","LU0985320562.USD","LU1057294990.SGD","LU0689626769.HKD","LU0053671581.USD","LU0980610538.SGD","LU0859254822.USD","LU1699723380.USD","LU0942090050.USD","IE00BFTCPJ56.SGD","IE00BSNM7G36.USD","LU1201861249.SGD","LU2023250843.SGD","LU0477156953.USD","MRK","LU1934455863.HKD","SG9999015341.SGD","LU0130517989.USD","LU0965509010.AUD","LU1162221912.USD","LU1116320901.HKD","LU0823416689.USD","LU2361044949.HKD","IE00B2B36J28.USD","LU1116320737.USD","LU0124676726.USD","IYH","LU1989771016.USD","LU1571399168.USD","LU2433249047.HKD","FTXH","LU0289739699.SGD","LU1066053197.SGD","SG9999014559.SGD","JDOC","LU1923622614.USD","LABU","LU2361045086.USD","LU1929549753.HKD","LU1066051811.HKD","LU2236285917.USD","LU1934455194.USD","IXJ","LU0432979614.USD","VHT","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673401459","title":"Exchange-Traded Funds Lower as US Equities Decline After Midday","url":"https://stock-news.laohu8.com/highlight/detail?id=2673401459","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673401459?lang=en_us&edition=fundamental","pubTime":"2026-10-08 01:10","pubTimestamp":1791393012,"startTime":"0","endTime":"0","summary":"Broad Market IndicatorsBroad-market exchange-traded funds IWM and IVV fell. Actively traded Invesco QQQ Trust (QQQ) eased 0.4%.US equity indexes fell ahead of the release of the Federal Reserve's Sept","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SHNY","XLV","CBOJ","XLPU","GBTC","USO","IYH","GLDY","BK4588","TECL","CBOY","VHT","XLY","BK4550","BTCI","USG","DEFI","BPI","KGLD","IYE","QQQ","SCO","IBB","SGOL","DGP","CBTO","BTC.USD.CC","VIS","QDEC","IBIT","MNRS","PSQ","NOCT","BTCW","ETQ","BK4504","CBXJ","BGLD","UNG","BITX","GLDM","CBTJ","XLF","AGQ","FAS","SIVR","DZZ","IGLD","XLP","SETH","QQQX","BETH","BTRN","RETL","BITB","EZBC","ETH.USD.CC","BITO","IGM","XLK","QID","GPIQ","TQQY","BK4570","BK4585","BTCC","GLD","ETH","ETHD","IYW","GLL","OUNZ","CBTY","XAUUSD.FOREX","BTCO","ESK","BCCC","BK4561","FBTC","HODL","CBOA","QLD","FGDL","EETH","CBXY","CBTA","XBTY","NJAN","SQQQ","NDX","YBTC","YGLD","CBXO","ETHT","BK4593","BTC","DGZ","ARKB","LABU","CBXA","FAZ","DFII","SLV","IAUM","QQQM","XAGUSD.FOREX","XLE","RTH","ZSL","BK4534","XLPD","BTF","XLI","SOXL","IAUI","CBOO","IYJ","BITY","NJUL","BFJL","BAR","SOXX","IAU","BTCL","UCO","VDC","BFAP","SOXS","UGL","XBI","TETH","TQQQ","BITU","BK4581","BETE","BAGY","MAXI","BITI","NAPR","QMAR","BRRR","ETCO","BTCZ","XRT","AAAU","QBF","SBIT","DULL","BK4547","XSD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673014180","title":"VERAXA Biotech (NASDAQ: VRXA) Advances FDA-Aligned Methods to Reduce Animal Testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2673014180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673014180?lang=en_us&edition=fundamental","pubTime":"2026-10-08 01:00","pubTimestamp":1791392422,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, October 7th, 2026, FinanceWire VERAXA Biotech (NASDAQ:VRXA), a developer of next-generation antibody-based cancer the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-fda-aligned-methods-to-reduce-animal-testing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-fda-aligned-methods-to-reduce-animal-testing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NDX","BK4139","JEPQ","BK4588","XBI","NVIW.SI","NQmain","TQQQ","LABU","BK4581","QYLG","QQQ","QID","GPIQ","TQQY","QQQM",".IXIC","BK4585","MNQmain","FTEC","PSQ","QQQA","QDTE","QQQE","03086","TECS","QQQJ","QLD","VRXA","SQQQ","QQQY","IYW","ONEQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673011717","title":"New Abdominoplasty Trial Signals Steady Demand in Procedure-Driven Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2673011717","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673011717?lang=en_us&edition=fundamental","pubTime":"2026-10-08 00:30","pubTimestamp":1791390623,"startTime":"0","endTime":"0","summary":"Lam Research Corp ($LRCX) announced an update on their ongoing clinical study. The study, formally titled “Prospective One-Year Evaluation of the S...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/new-abdominoplasty-trial-signals-steady-demand-in-procedure-driven-healthcare?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/new-abdominoplasty-trial-signals-steady-demand-in-procedure-driven-healthcare?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1496350502.SGD","LRCU","LU0942090050.USD","LU1548497426.USD","RDVY","LU2357305700.SGD","RULE","BK4543","LRCC","CLSE","LU1066053197.SGD","KNOW","LU2244417387.USD","LU0320765059.SGD","BOBP","HCSG","LU0868494708.USD","XBI","LU0187121727.USD","EPAI","IE00B1XK9C88.USD","IE00BJJMRY28.SGD","LU0157215616.USD","BK4137","IE00BQXX3C00.GBP","QQQG","IETC","ABFL","LU1992135399.USD","PSI","XLV","LU0210536198.USD","LU1244550221.USD","TEK","LRCX","LU0672654240.SGD","BK4588","LU1066051811.HKD","LU0061474960.USD","BAI","LABU","LU2931357623.SGD","BK4581","RDVI","TDV","LU1974910355.USD","TINY","LU2089985449.USD","LU1674673691.USD","COWG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673117740","title":"Community Healthcare management to meet virtually with Truist","url":"https://stock-news.laohu8.com/highlight/detail?id=2673117740","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673117740?lang=en_us&edition=fundamental","pubTime":"2026-10-08 00:30","pubTimestamp":1791390612,"startTime":"0","endTime":"0","summary":"Analyst Lewis holds a virtual meeting with management on October 7 hosted by Truist. Published first on TheFly – the ultimate source for real-time,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/community-healthcare-management-to-meet-virtually-with-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/community-healthcare-management-to-meet-virtually-with-truist-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4588","XBI","BK4585","BK4581","CHCT","BK4225","KBWY","XLV","BK4203"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673011517","title":"Novartis announces FDA approval of Rhapsido for symptomatic dermographism","url":"https://stock-news.laohu8.com/highlight/detail?id=2673011517","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673011517?lang=en_us&edition=fundamental","pubTime":"2026-10-07 23:50","pubTimestamp":1791388212,"startTime":"0","endTime":"0","summary":"Novartis (NVS) announced that the Food and Drug Administration approved Rhapsido as the first treatment for adults with symptomatic dermographism i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-announces-fda-approval-of-rhapsido-for-symptomatic-dermographism-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-announces-fda-approval-of-rhapsido-for-symptomatic-dermographism-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FRTY","BK4532","LFSC","IE0009355771.USD","NVS","PINK","IEIH","MEDI","GDOC","BBP","LU0208291251.USD","LU0211331839.USD","IE00B4R5TH58.HKD","RSPH","TBXU","IE00BJJMRZ35.SGD","IE0002141913.USD","IDNA","NVIB","XLVX","GNMX","IE00B2B36J28.USD","MEDX","BMED","SYNB","PPH","LABU","TECB","IE00BJT1NW94.SGD","BK4585","BK4007","IYH","IBB","MRNY","IE00BFTCPJ56.SGD","MRNX","LU0320765489.SGD","LU0070302665.USD","PSCH","BK4588","BK4578"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673118620","title":"Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673118620","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673118620?lang=en_us&edition=fundamental","pubTime":"2026-10-07 23:45","pubTimestamp":1791387900,"startTime":"0","endTime":"0","summary":"In Phase III RemIND trial, twice as many adults taking Rhapsido achieved complete hive resolution by Week 12 vs placebo, with responses seen by Week 21SD is most prevalent type of chronic inducible ur","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/07/3376686/0/en/novartis-rhapsido-remibrutinib-receives-fda-approval-as-first-treatment-for-symptomatic-dermographism-sd-expanding-its-use-beyond-chronic-spontaneous-urticaria-csu.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106831901.USD","RSPH","LU1244550221.USD","MEDI","BBP","BK4581","IE00B3S45H60.SGD","IAI","LU0267386448.USD","LU0795875169.SGD","SYNB","TBXU","LU1064131342.USD","IYH","LU0390134368.USD","BMED","IE00BZ1G4Q59.USD","KBWB","LU2023251221.USD","IDNA","GNMX","GDOC","LU2264538146.SGD","FRTY","LU2487616109.SGD","MRNY","PSCH","LABU","BK4504","LU0210528500.USD","LU1720051017.SGD","TECB","XLVX","LU0528227936.USD","BK4585","NVIB","LU0912757837.SGD","LU1720051108.HKD","MRNX","IBB","LU1668664300.SGD","LU2357305700.SGD","SD","LFSC","LU2028103732.USD","LU1791710582.SGD","LU1989772840.SGD","LU2089284900.SGD","PINK","IEIH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673016634","title":"Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST) and Stryker (SYK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673016634","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673016634?lang=en_us&edition=fundamental","pubTime":"2026-10-07 22:00","pubTimestamp":1791381626,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Envista Holdings (NVST) and Stryker (SYK) with bulli...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-envista-holdings-nvst-and-stryker-syk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-envista-holdings-nvst-and-stryker-syk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z6F94.USD","BK4588","BK4082","BK4585","LU0882574055.USD","LU1201861165.SGD","SYK","LU2362541273.HKD","LU0289739699.SGD","LU0432979614.USD","LU0130103400.USD","LU0950375773.USD","XBI","LU2506951958.HKD","LU0690374961.EUR","LU2506951875.HKD","IE0034390439.USD","LU1983299246.USD","LU2324357040.USD","BK4504","LU2468319806.SGD","BK4137","LU0058720904.USD","LU0130518102.USD","IHI","LU0114720955.EUR","LU1791710400.SGD","LU2404859741.USD","LU2404859667.USD","LU0648000940.SGD","LU2089984988.USD","LU2506952170.USD","LU2362540622.SGD","NVST","LU0823417737.USD","LABU","BK4566","LU0029874061.USD","LU0528227936.USD","LU0477156797.USD","LU0128526141.USD","BK4581","GB00B4QBRK32.GBP","LU2362541513.USD","XLV","LU1791710582.SGD","HCSG","LU0690374615.EUR","LU0823417653.USD","LU2506952097.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673015601","title":"Ultragenyx Monetizes FDA Priority Review Voucher Asset","url":"https://stock-news.laohu8.com/highlight/detail?id=2673015601","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673015601?lang=en_us&edition=fundamental","pubTime":"2026-10-07 21:32","pubTimestamp":1791379976,"startTime":"0","endTime":"0","summary":"Ultragenyx Pharmaceutical ( ($RARE) ) has issued an update. On October 6, 2026, Ultragenyx Pharmaceutical Inc. entered into an asset purchase agree...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ultragenyx-monetizes-fda-priority-review-voucher-asset?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ultragenyx-monetizes-fda-priority-review-voucher-asset?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673159350","title":"Clearmind Medicine submits psychedelic therapy recommendations to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2673159350","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673159350?lang=en_us&edition=fundamental","pubTime":"2026-10-07 21:25","pubTimestamp":1791379525,"startTime":"0","endTime":"0","summary":"Clearmind Medicine (CMND) announced it submitted recommendations to the FDA under Docket FDA-2026-N-7542 on future therapeutic use of psychedelic d...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-submits-psychedelic-therapy-recommendations-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/clearmind-medicine-submits-psychedelic-therapy-recommendations-to-fda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","PSIL","LABU","CMND","BK4585","PSYK","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673130070","title":"Sector Update: Healthcare Stocks Flat to Higher Pre-Bell Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2673130070","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673130070?lang=en_us&edition=fundamental","pubTime":"2026-10-07 21:22","pubTimestamp":1791379373,"startTime":"0","endTime":"0","summary":"Healthcare stocks were flat to higher pre-bell Wednesday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.4%.Danaher (DHR) stock wa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DHR","IE00BKVL7J92.USD","SGXZ57979304.SGD","BK4137","FMED","BK4121","IE00BQXX3C00.GBP","SG9999004303.SGD","LU0289960550.SGD","LU1551013425.SGD","XLV","BK4588","LABU","LU1267930730.SGD","LU0114720955.EUR","LU2106854487.HKD","BK4504","XBI","DHR.AU","LU0882574055.USD","LU0320765059.SGD","ARWR","SG9999013999.USD","LU0689472784.USD","LU2125910179.SGD","LU2355687059.USD","LU2112291526.USD","IE00BZ1G4Q59.USD","LU0187121727.USD","LU0289739343.SGD","LU0528227936.USD","SG9999001176.SGD","LU0122379950.USD","BK4533","LU1061106388.HKD","IBB","LU1023059063.AUD","BK4534","NEOG","BK4581","LU1791710582.SGD","IE0004445239.USD","IE00BQXX3F31.USD","LU0312595415.SGD","LU0820562030.AUD","IE000M9KFDE8.USD","LU1804176565.USD","LU2125909247.SGD","HCSG","LU2265009873.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673901382","title":"Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2673901382","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673901382?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:40","pubTimestamp":1791376800,"startTime":"0","endTime":"0","summary":"Company Calls for Consideration of New Regulatory Pathways and Cost Saving of Non-Hallucinogenic Neuroplastogens for Alcohol Use Disorder Vancouver, Canada, Oct.  07, 2026 (GLOBE NEWSWIRE) --  Clearmi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/07/3376478/0/en/clearmind-advances-dialogue-with-u-s-federal-government-on-psychedelic-therapies-submitting-recommendations-to-fda.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4009","LABU","HHS","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673018273","title":"AbbVie’s telisotuzumab adizutecan gets two FDA Breakthrough Therapy Designations","url":"https://stock-news.laohu8.com/highlight/detail?id=2673018273","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673018273?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:36","pubTimestamp":1791376566,"startTime":"0","endTime":"0","summary":"AbbVie (ABBV) announced that the U.S. FDA has granted two Breakthrough Therapy Designations for telisotuzumab adizutecan in colorectal cancer and n...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abbvies-telisotuzumab-adizutecan-gets-two-fda-breakthrough-therapy-designations-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abbvies-telisotuzumab-adizutecan-gets-two-fda-breakthrough-therapy-designations-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLAM","SG9999015986.USD","LU1670627923.USD","LU2089284900.SGD","BK4559","LU1551013425.SGD","XLV","LU0708994859.HKD","LABU","LU1989772923.USD","RXL","IE00BGHQF631.EUR","LU2237443549.SGD","IE00BLSP4239.USD","MEDX","PJP","LU1496350171.SGD","LU0689472784.USD","LU0417517546.SGD","FTXH","IE00B19Z3581.USD","LU0029864427.USD","SG9999015978.USD","LU0965508806.USD","FHLC","LU2112291526.USD","IE00BJT1NW94.SGD","AGNG","IE000F7OJYX1.SGD","LU1548497426.USD","JDOC","BK4581","LU1496350502.SGD","LU1989772840.SGD","VHT","LU1839511570.USD","SG9999003800.SGD","IE00BN8TJ469.HKD","PPH","IE0004445239.USD","LU0158827948.USD","TRUH","BK4550","IXJ","IYH","IE00B4R5TH58.HKD","LU0456855351.SGD","LU1093756325.SGD","ABBV","LU0738911758.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673203018","title":"Analysts Conflicted on These Healthcare Names: BridgeBio Pharma (BBIO) and Vaxcyte (PCVX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673203018","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673203018?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:30","pubTimestamp":1791376237,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on BridgeBio Pharma (BBIO) and Vaxcyte (PCVX). BridgeBio Pharma (BBI...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-bridgebio-pharma-bbio-and-vaxcyte-pcvx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-bridgebio-pharma-bbio-and-vaxcyte-pcvx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","IE0009354923.USD","BK4505","LABU","LU0053671581.USD","BK4588","BK4139","BBIO","BK4585","HCSG","XBI","XLV","PCVX","BK4581","LU0029874061.USD","BK4137"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":22,"pageCount":3,"totalSize":425,"code":"91000000","status":"200"}]}}